US FDA OKs Cadila Healthcare topicals plant

By Staff reporter

- Last updated on GMT

US FDA OKs Cadila Healthcare topicals plant

Related tags: Food and drug administration

Cadila Healthcare Limited says its topical drug manufacturing plant has passed an inspection by the US Food and Drug Administration (FDA).

According to a Bombay Stock Exchange (BSE) filing​, the Cadila plant in Changodar in Ahmedabad passed an inspection conducted by the US regulator last week with no Form 483 observations.

The facility manufacturers 17 generic topical pharmaceutical products for the US market according to Cadila.

Related news

Related products

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Spray Dried Powders for High Dose Drug Delivery

Spray Dried Powders for High Dose Drug Delivery

Catalent | 01-Feb-2022 | Product Presentation

This Catalent webinar will explore how spray dried particles provide an attractive, carrier-free option for highly dispersed delivery of API to deep lung...

Related suppliers

Follow us

Products

View more

Webinars